Analyst likes Cell Therapeutics (9/29/03)
- MATTHEW L. KAPLAN, Punk Ziegel & Company
- Drug Delivery

Analyst recommends AVI BioPharma (8/28/03)
- RENI BENJAMIN, PHD, Rodman and Renshaw
- Biotechnology

Analyst says Geron has cancer vaccine data coming up that could move the stock significantly (8/28/03)
- RENI BENJAMIN, PHD, Rodman and Renshaw
- Biotechnology

Financial Director sees partners international diversity as edge (8/26/03)
- HP WIESE, Global Life Sciences Ventures
- Biotechnology

Finance Director says Crucell's success lies in licensing for development (8/26/03)
- LEONARD KRUIMER, Crucell
- Biotechnology

Chief Executive sees out lisencing and partnering as keys to drug discovery programs (8/26/03)
- RAINER WESSEL, Axxima Pharmaceuticals AG
- Biotechnology

CEO says Cellzome stands alone with the pathway expansion technology (8/26/03)
- DR. DAVID BROWN, Cellzome
- Biotechnology

Vice President views fundamental changes in hospital staff habits as key to improving efficiency (8/26/03)
- ALEXIS WESTERMANN, Medasys
- Biotechnology

Analyst says CollaGenex is an earnings story (8/26/03)
- RENI BENJAMIN, PHD, Rodman and Renshaw
- Biotechnology

CEO discusses Amarin Corporation’s renegotiation of financial obligations to Elan (8/19/03)
- RICK STEWART, Amarin Corporation Plc
- Pharmaceuticals

Chief Business Officer of Pharming Group talks about products in clinical trials (8/6/03)
- REIN STRIJKER, Pharming Group
- Biotechnology

CEO of Novartis says pipeline is one of the strongest in the industry (8/6/03)
- DANIEL VASELLA, Novartis AG
- Pharmaceuticals

CEO of DNAprint genomics predicts revenues to grow over next 24 months (8/1/03)
- TONY FRUDAKIS, DNAprint genomics, Inc.
- Biotechnology

Chief Executive of Genarea defines new goals after cash crisis (7/31/03)
- DR. ROY CLIFFORD LEVITT, Genaera Corporation
- Biotechnology

CEO of DOV Pharmaceutical, Inc. reveals potential blockbusters (7/31/03)
- ARNOLD S. LIPPA, DOV Pharmaceutical, Inc.
- Pharmaceuticals

CEO of Amarillo Biosciences, Inc. talks about orphan drugs development (7/30/03)
- JOSEPH M. CUMMINGS, Amarillo Biosciences, Inc.
- Biotechnology

CEO of Genaera Corporation talks about its competitive advantages over chronic needle injections (7/29/03)
- DR. ROY CLIFFORD LEVITT, Genaera Corporation
- Biotechnology

CE says Oxford Biomedica's cancer products perform brilliantly in intial clinical trials (7/28/03)
- DR. ALAN KINGSMAN, Oxford BioMedica PLC
- Biotechnology

CEO of Phytopharm discusses potential of botanical drug discovery platforms (7/28/03)
- RICHARD PETER DIXEY, Phytopharm Plc
- Biotechnology

Executive Chairman of ReGen Therapeutics Plc discusses three key business objectives (7/28/03)
- PERCY LOMAX, ReGen Therapeutics Plc
- Biotechnology

COO says CeNeS Pharmaceuticals is fully funded to meet clinical milestones for the next 18-24 months (7/28/03)
- NEIL R. CLARK, CeNeS Pharmaceuticals plc
- Biotechnology

CEO of Protherics says the business is moving into profit and can cover its own costs (7/28/03)
- ANDREW HEATH, Protherics Plc
- Biotechnology

Vivus is rated highly by Analyst (7/28/03)
- DR. RUSSELL GILBERTSON, Roth Capital Partners
- Biotechnology

CEO highlights the competitive environment for BioCryst Pharmaceuticals (7/28/03)
- CHARLES E. BUGG, BioCryst Pharmaceuticals
- Biotechnology

CEO of Applied Molecular Evolution explains the business model (7/28/03)
- WILLIAM D. HUSE, Applied Molecular Evolution
- Biotechnology

CEO of The TriZetto Group expects organic growth in the 13%-19% range for 2003 (7/23/03)
- JEFFREY H. MARGOLIS, The TriZetto Group
- Pharmaceuticals

CEO of Women First HealthCare talks about the strategy for the next two years (7/23/03)
- EDWARD F. CALESA, Women First HealthCare, Inc.
- Pharmaceuticals

CEO of Cobra Biomanufacturing Plc discusses long term upside potential from product sale royalties (6/18/03)
- DAVID THATCHER, Cobra Biomanufacturing Plc
- Pharmaceuticals

Direct link - www.twst.com/notes/drugs_biot 

TOP